HK1256965A1 - γ羥基丁酸與單羧酸轉運蛋白的施用 - Google Patents

γ羥基丁酸與單羧酸轉運蛋白的施用

Info

Publication number
HK1256965A1
HK1256965A1 HK18116105.8A HK18116105A HK1256965A1 HK 1256965 A1 HK1256965 A1 HK 1256965A1 HK 18116105 A HK18116105 A HK 18116105A HK 1256965 A1 HK1256965 A1 HK 1256965A1
Authority
HK
Hong Kong
Prior art keywords
administration
gamma hydroxybutyrate
monocarboxylate transporters
monocarboxylate
transporters
Prior art date
Application number
HK18116105.8A
Other languages
English (en)
Inventor
馬克‧埃勒
Original Assignee
杰資製藥愛爾蘭有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51031733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1256965(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 杰資製藥愛爾蘭有限公司 filed Critical 杰資製藥愛爾蘭有限公司
Publication of HK1256965A1 publication Critical patent/HK1256965A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
HK18116105.8A 2013-03-01 2018-12-14 γ羥基丁酸與單羧酸轉運蛋白的施用 HK1256965A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361771557P 2013-03-01 2013-03-01
US201361777873P 2013-03-12 2013-03-12
US13/837,714 US9050302B2 (en) 2013-03-01 2013-03-15 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/873,000 US8952029B2 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US13/872,997 US8772306B1 (en) 2013-03-01 2013-04-29 Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Publications (1)

Publication Number Publication Date
HK1256965A1 true HK1256965A1 (zh) 2019-10-04

Family

ID=51031733

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16103516.1A HK1215539A1 (zh) 2013-03-01 2016-03-24 γ羥基丁酸與單羧酸轉運蛋白的施用
HK18116105.8A HK1256965A1 (zh) 2013-03-01 2018-12-14 γ羥基丁酸與單羧酸轉運蛋白的施用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK16103516.1A HK1215539A1 (zh) 2013-03-01 2016-03-24 γ羥基丁酸與單羧酸轉運蛋白的施用

Country Status (22)

Country Link
US (10) US9050302B2 (zh)
EP (3) EP3695833A1 (zh)
JP (1) JP6433440B2 (zh)
KR (1) KR102239042B1 (zh)
CN (2) CN105073106A (zh)
AU (1) AU2014223373B2 (zh)
BR (1) BR112015021012A8 (zh)
CA (1) CA2902948C (zh)
CY (2) CY1120086T1 (zh)
DK (2) DK3335708T3 (zh)
ES (2) ES2659284T3 (zh)
HK (2) HK1215539A1 (zh)
HR (1) HRP20200215T1 (zh)
IL (1) IL240874B (zh)
LT (1) LT3335708T (zh)
MX (1) MX2015011242A (zh)
PL (2) PL2961399T3 (zh)
PT (2) PT2961399T (zh)
SG (1) SG11201505029QA (zh)
SI (1) SI3335708T1 (zh)
TW (1) TWI619492B (zh)
WO (1) WO2014134380A1 (zh)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) * 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
EP4119539A1 (en) 2015-09-23 2023-01-18 XWPharma Ltd. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10829443B2 (en) 2016-09-06 2020-11-10 Jazz Pharmaceuticals Ireland Limited Solvate form of (R)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
ES2964943T3 (es) 2016-10-06 2024-04-10 Axsome Malta Ltd Compuestos de carbamoilfenilalaninol para uso médico
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
KR20200016889A (ko) 2017-06-02 2020-02-17 재즈 파마슈티칼즈 아일랜드 리미티드 과다 졸림증을 치료하기 위한 방법 및 조성물
CN111094238B (zh) 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
MX2020002741A (es) * 2017-09-12 2020-07-21 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento de narcolepsia.
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
KR20220119429A (ko) 2019-12-24 2022-08-29 재즈 파마슈티칼즈 아일랜드 리미티드 감마-히드록시부티레이트(ghb) 투약
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
CN115397406A (zh) * 2020-04-16 2022-11-25 弗拉梅尔爱尔兰有限公司 施用γ-羟基丁酸组合物与双丙戊酸钠的方法
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202228665A (zh) 2020-10-05 2022-08-01 凱瑞康寧生技股份有限公司 γ－羥基丁酸衍生物之修飾釋放組合物
US20230404950A1 (en) 2020-10-08 2023-12-21 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CA3195856A1 (en) 2020-10-16 2022-04-21 Franck SKOBIERANDA Treatment methods using ghb
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE237309C (zh)
US797171A (en) 1904-08-04 1905-08-15 Antonio Cerruti Fruit-washer.
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
GB922029A (en) 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
GB971700A (en) 1961-02-02 1964-09-30 Boots Pure Drug Co Ltd Anti-Inflammatory Agents
FR2442M (fr) 1962-10-17 1964-04-06 Henry Eugene L'acide dipropylacétique et ses dérivés en tant que nouveuax médicaments dépresseurs du systeme nerveux central.
FR2383920A1 (fr) 1977-03-15 1978-10-13 Labaz Procede de preparation d'un derive d'acetonitrile et derive obtenu par ce procede
US4155929A (en) 1977-05-25 1979-05-22 Labaz Process for the preparation of an acetonitrile derivative
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
JPS61186319A (ja) * 1985-02-12 1986-08-20 Res Dev Corp Of Japan 睡眠覚醒調節剤
DD237309A1 (de) 1985-05-15 1986-07-09 Berlin Chemie Veb Verfahren zur herstellung eines lagerstabilen natriumsalzes der gamma-hydroxybuttersaeure
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
US4983612A (en) 1989-10-05 1991-01-08 American Home Products Corporation Antihypertensive benzopyran derivatives
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
IT1271403B (it) 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
US5833599A (en) 1993-12-13 1998-11-10 Multum Information Services Providing patient-specific drug information
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US7072840B1 (en) 1994-10-28 2006-07-04 Cybear, L.L.C. Prescription management system
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5758095A (en) 1995-02-24 1998-05-26 Albaum; David Interactive medication ordering system
US6112182A (en) 1996-01-16 2000-08-29 Healthcare Computer Corporation Method and apparatus for integrated management of pharmaceutical and healthcare services
US5990162A (en) 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
DE69907508T2 (de) * 1998-12-23 2003-11-20 Orphan Medical Inc Mikrobenbeständige und stabilisierte lösungen, die gamma-hydroxybuttersäuresalze zur behandlung von narkolepsie enthalten
US6067524A (en) 1999-01-07 2000-05-23 Catalina Marketing International, Inc. Method and system for automatically generating advisory information for pharmacy patients along with normally transmitted data
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US6383764B1 (en) * 2000-04-28 2002-05-07 The Regents Of The University Of California Methods of identifying compounds for controlling absence seizures in a mammal relating to prolactin-releasing peptide(PrRP)
EP1325014B1 (en) 2000-09-22 2012-05-23 JPI Commercial, LLC Gamma-hydroxybutyrate compositions containing carbohydrate carriers
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
RU2232012C1 (ru) 2003-06-02 2004-07-10 Иркутский государственный медицинский университет Способ лечения бруксизма
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
CA2586975A1 (en) 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
US20110145018A1 (en) * 2005-03-21 2011-06-16 Fotsch Edward J Drug and medical device safety and support information reporting system, processing device and method
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
CN102946869B (zh) * 2010-05-04 2016-08-03 爵士制药有限公司 γ-羟基丁酸的速释制剂及剂型
CN103221535A (zh) 2010-09-16 2013-07-24 康奈尔大学 腺苷受体信号转导调节血脑屏障通透性的用途
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en) 2016-07-22 2023-09-26 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en) 2016-07-22 2023-11-28 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en) 2016-07-22 2023-12-12 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en) 2016-07-22 2024-02-13 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number Publication date
DK3335708T3 (da) 2020-02-24
HRP20200215T1 (hr) 2020-05-15
JP2016510031A (ja) 2016-04-04
US10864181B2 (en) 2020-12-15
EP2961399B1 (en) 2017-11-15
ES2775779T3 (es) 2020-07-28
US9050302B2 (en) 2015-06-09
CN105073106A (zh) 2015-11-18
CY1122992T1 (el) 2021-10-29
LT3335708T (lt) 2020-05-11
EP2961399A1 (en) 2016-01-06
KR20150125943A (ko) 2015-11-10
US11253494B2 (en) 2022-02-22
IL240874A0 (en) 2015-10-29
JP6433440B2 (ja) 2018-12-05
SG11201505029QA (en) 2015-07-30
CY1120086T1 (el) 2018-12-12
AU2014223373A1 (en) 2015-08-20
US20180200210A1 (en) 2018-07-19
PL2961399T3 (pl) 2018-05-30
PT3335708T (pt) 2020-03-17
BR112015021012A8 (pt) 2019-11-26
EP3335708B1 (en) 2019-12-11
US8772306B1 (en) 2014-07-08
CN111317730A (zh) 2020-06-23
IL240874B (en) 2019-06-30
EP3695833A1 (en) 2020-08-19
US20190274980A1 (en) 2019-09-12
PT2961399T (pt) 2018-02-21
US20170049731A1 (en) 2017-02-23
BR112015021012A2 (pt) 2017-07-18
US20160015662A1 (en) 2016-01-21
SI3335708T1 (sl) 2020-04-30
US20140249115A1 (en) 2014-09-04
PL3335708T3 (pl) 2020-08-24
US9486426B2 (en) 2016-11-08
ES2659284T3 (es) 2018-03-14
US20210212970A1 (en) 2021-07-15
HK1215539A1 (zh) 2016-09-02
WO2014134380A1 (en) 2014-09-04
US8952029B2 (en) 2015-02-10
CA2902948A1 (en) 2014-09-04
US20210128502A1 (en) 2021-05-06
CA2902948C (en) 2019-12-31
TW201511752A (zh) 2015-04-01
TWI619492B (zh) 2018-04-01
DK2961399T3 (en) 2018-02-19
MX2015011242A (es) 2016-05-31
KR102239042B1 (ko) 2021-04-12
US10213400B2 (en) 2019-02-26
AU2014223373B2 (en) 2018-12-06
EP3335708A1 (en) 2018-06-20
US20220193015A1 (en) 2022-06-23
US20140249222A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
HRP20200215T1 (hr) Davanje gama hidroksibutirata s transporterima monokarboksilata
HRP20180635T1 (hr) Pirazolamidni spoj i njegova upotreba u medicini
HRP20180684T1 (hr) Kombinacija lijekova
EP4005604C0 (en) ADMINISTRATION OF MEDICINES
HUE052233T2 (hu) Nem immunszuppresszív, antigénre specifikus immunterápiás ágensek ismételt beadása
IL290486A (en) Subcutaneous administration of adamts13
EP2965773A4 (en) SYRINGE AND SPRAY SEAL
GB2533513B (en) Structure of pixel
EP2982311A4 (en) MEDICAL TUBE AND ARRANGEMENT WITH THE MEDICAL TUBE
HK1213638A1 (zh) 免疫增強藥物的納米載體
EP2999427A4 (en) PARAXYLOL FILMS AND THERAPEUTIC USES THEREOF
GB201319437D0 (en) Delivery of drugs
GB201319595D0 (en) Combination of Analgesic drugs
GB201320786D0 (en) Medicament
GB201316468D0 (en) Combination of analgesic drugs